CN114081899A - Preparation method of leukocyte-rich and platelet-rich plasma - Google Patents
Preparation method of leukocyte-rich and platelet-rich plasma Download PDFInfo
- Publication number
- CN114081899A CN114081899A CN202111287905.8A CN202111287905A CN114081899A CN 114081899 A CN114081899 A CN 114081899A CN 202111287905 A CN202111287905 A CN 202111287905A CN 114081899 A CN114081899 A CN 114081899A
- Authority
- CN
- China
- Prior art keywords
- prp
- group
- rich
- wound
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000265 leukocyte Anatomy 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 210000004623 platelet-rich plasma Anatomy 0.000 title claims abstract description 11
- 206010052428 Wound Diseases 0.000 claims abstract description 44
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 44
- 210000004369 blood Anatomy 0.000 claims abstract description 36
- 239000008280 blood Substances 0.000 claims abstract description 36
- 210000004027 cell Anatomy 0.000 claims description 21
- 238000005119 centrifugation Methods 0.000 claims description 15
- 210000002381 plasma Anatomy 0.000 claims description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- 238000007664 blowing Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 210000003743 erythrocyte Anatomy 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 27
- 102000004889 Interleukin-6 Human genes 0.000 abstract description 26
- 230000029663 wound healing Effects 0.000 abstract description 12
- 238000013518 transcription Methods 0.000 abstract description 9
- 230000035897 transcription Effects 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 230000029774 keratinocyte migration Effects 0.000 abstract description 6
- 230000007246 mechanism Effects 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 230000003213 activating effect Effects 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 239000010836 blood and blood product Substances 0.000 abstract description 2
- 229940125691 blood product Drugs 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 230000019491 signal transduction Effects 0.000 abstract description 2
- 229940100601 interleukin-6 Drugs 0.000 abstract 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 abstract 1
- 230000035876 healing Effects 0.000 description 17
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 16
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 230000005012 migration Effects 0.000 description 16
- 238000013508 migration Methods 0.000 description 16
- 230000008569 process Effects 0.000 description 13
- 210000002510 keratinocyte Anatomy 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 9
- 102100025818 Major prion protein Human genes 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 208000000283 familial pityriasis rubra pilaris Diseases 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 5
- 230000012292 cell migration Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 210000000940 dendritic epidermal T lymphocyte Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 229940124790 IL-6 inhibitor Drugs 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 210000001631 vena cava inferior Anatomy 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- ANMATWQYLIFGOK-UHFFFAOYSA-N Iguratimod Chemical compound CS(=O)(=O)NC1=CC=2OC=C(NC=O)C(=O)C=2C=C1OC1=CC=CC=C1 ANMATWQYLIFGOK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- 210000003592 T-IEL Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000007646 directional migration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- QHQPAWAPIKTLIR-UHFFFAOYSA-N idesin Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=CC=C1CO QHQPAWAPIKTLIR-UHFFFAOYSA-N 0.000 description 1
- 229950003909 iguratimod Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000005128 keratinized epithelium Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B04—CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL OR CHEMICAL PROCESSES
- B04B—CENTRIFUGES
- B04B5/00—Other centrifuges
- B04B5/04—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers
- B04B5/0407—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers for liquids contained in receptacles
- B04B5/0414—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers for liquids contained in receptacles comprising test tubes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of blood products, and discloses a preparation method of leukocyte-rich and platelet-rich plasma (L-PRP), which comprises the steps of collecting blood and preparing the L-PRP; also discloses the application of the L-PRP in wound treatment. The platelet content of the L-PRP prepared by the invention is about 4 times of that of whole blood, and the L-PRP is rich in white blood cells and interleukin 6(IL-6), and the L-PRP is found to promote keratinocyte migration to accelerate wound re-epithelialization by up-regulating IL-6 transcription level and activating signal transduction and transcriptional activation protein 3(STAT 3); the L-PRP prepared by the invention and the research on the L-PRP refine the classification and application scenes of platelet-rich plasma (PRP), discover a new mechanism for promoting wound healing by the L-PRP, provide a new solution for clinically solving the difficult wound, and have important clinical practice significance.
Description
Technical Field
The invention relates to the technical field of blood products, in particular to a preparation method of leukocyte-rich and platelet-rich plasma.
Background
Refractory wounds refer to the phenomena of delayed or interrupted physiological healing due to insufficient angiogenesis, nerve loss, cell migration disorder, etc., and are generally defined as wounds with healing time longer than 3 months. Many diseases can affect wound healing, and with the more serious problems of aging, smoking, obesity, diabetes and the like all over the world, the incidence of the wound which is difficult to heal is gradually increased. This not only causes pain, infection, and even disability, amputation, and psychological problems for the patient, but also places a huge economic burden on society. Therefore, how to promote the wound healing becomes an important proposition to be solved urgently by clinicians.
Restoration of wound epithelialization to an intact skin barrier is an essential feature of wound healing completion, also known as re-epithelialization. The directed migration of keratinocytes is critical for wound epithelialization, and the deficiency in this function is closely associated with chronic refractory wounds. The re-epithelialization of the wound is achieved as a result of keratinocyte migration, proliferation and differentiation, which begins with the release of cell-cell and cell-matrix contact; next, the basal layer keratinocytes start to polarize and initiate migration on the wound matrix, while the keratinocytes start to proliferate by division next to the wound margins; finally, the newly formed epidermis is differentiated into a multilayered structure to restore the function of the epidermis. The most limiting step in the re-epithelialization process is the migration of keratinocytes. Parakeratosis and hyperkeratosis are characteristics of keratinocytes of a chronic wound, and the functional defect of migration of the keratinocytes is most related to chronic hard-to-heal wounds, so that the regulation of the migration of the keratinocytes in the process of wound healing and re-epithelialization is a key factor for promoting the healing of the chronic wound.
Research shows that the IL-6/STAT3 pathway is very critical in promoting wound re-epithelialization and skin barrier recovery, the IL-6-deficient mouse wound re-epithelialization is remarkably delayed, and IL-6 gene is introduced into keratinocytes to promote the proliferation of the keratinocytes. IL-6 is a typical upstream ligand of STAT3 signal transduction pathway, and STAT3 phosphorylation and nuclear translocation occur within 30 minutes after stimulation after keratinocytes are treated with recombinant IL-6 in vitro, and the intracellular phosphorylation signaling and activator of transcription 3(pSTAT3) content increases with time (30min to 6 h). IL-6 activates STAT3 in skin fibroblasts, causing it to secrete soluble factors, which in turn mediate keratinocyte migration. IL-6 mediated pSTAT3 signaling drives transcription of the keratinized epithelium Skint (selection and up-keep of intraepithelial T-cells) gene of acute wounds of young mice, activates Dendritic Epidermal T Cells (DETCs) to promote wound healing, and weakens the signal path in the wounds of delayed healing of old mice. Skint expression is directly affected by STAT3 signaling, knocking out the epidermal STAT3 gene affects the number and activation of periwound DETCs, which in turn affects delayed wound healing, STAT3 is its key role in keratinocyte migration signaling, rather than its proliferation, and STAT3 is essential for skin remodeling, including hair cycle and wound healing. In addition, IL-6 can obviously promote the migration of corneal epithelial cells in vitro, and after 6 hours of treatment, the content of pSTAT3 can be detected to be remarkably increased. Therefore, the IL-6/STAT3 pathway is very important for keratinocyte migration, and activation of the pathway can effectively promote re-epithelialization and accelerate wound healing.
Disclosure of Invention
In view of the above problems, the present invention provides a method for preparing leukocyte-rich platelet-rich plasma (L-PRP) having a platelet content of about 4 times that of whole blood and being rich in leukocytes and IL-6.
In order to solve the technical problems, the invention provides a preparation method of L-PRP, which comprises the following specific steps: collecting 10mL of whole blood by using a 10mL EDTA vacuum blood collection purple head tube, then placing the purple head tube filled with the whole blood at 4 ℃ for 200g for centrifugation for 10min, clearly dividing the whole blood into three parts, sequentially forming a clear light yellow plasma layer, a white flocculent white membranous layer and a red blood cell layer with the maximum density from top to bottom, sucking the three parts to a position 2mm below the white membranous layer by using a 1mL sterile suction pipe, moving the three parts to a 15mL clean centrifugal tube, discarding the rest components, leaving 1mL of plasma in the centrifugal tube, carefully suspending cell masses at the bottom of the centrifugal tube by using the sterile suction pipe, gently blowing and uniformly suspending the suspension to obtain 1mL light blood color L-PRP, wherein the part in the centrifugal tube needs to contain all upper plasma layers and all white membranous layers, and then performing secondary centrifugation, and the secondary centrifugation condition is 200g for 10min at 4 ℃.
In order to solve the technical problems, the invention also provides the L-PRP.
In order to solve the technical problems, the invention also provides application of the L-PRP in a medicament for treating the wound surface which is difficult to heal.
Compared with the prior art, the invention has the beneficial effects that: the platelet content of the L-PRP prepared by the invention is about 4 times of that of whole blood, the L-PRP is rich in leukocytes and IL-6, and the L-PRP is found to promote keratinocyte migration to accelerate wound surface re-epithelialization by up-regulating IL-6 transcription level and activating STAT 3; the L-PRP prepared by the invention and the research on the L-PRP refine the classification and application scenes of the PRP, discover a new mechanism for promoting the healing of the wound surface by the L-PRP, provide a new solution for clinically solving the difficult wound surface, and have important clinical practice significance.
Drawings
FIG. 1 is a schematic diagram of the preparation process and content measurement of PRP in the embodiment of the present invention;
FIG. 2 is a graph showing the results of an experiment in which L-PRP promotes re-epithelialization of rat wound according to an embodiment of the present invention;
FIG. 3 is a graph showing the results of transcription levels of proinflammatory factors in periwound tissue according to embodiments of the invention;
FIG. 4 is a graph showing the effect of L-PRP on the transcription level of IL-6 from HaCaT cells according to an embodiment of the present invention;
FIG. 5 is a graph showing the results of a cell scratch test according to an embodiment of the present invention;
FIG. 6 is a graph showing the results of a cell migration experiment according to an embodiment of the present invention;
FIG. 7 is a graph showing the effect of L-PRP on the level of STAT3 activation by HaCaT cells in accordance with an embodiment of the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail below with reference to examples and accompanying drawings, and the exemplary embodiments and descriptions thereof are only used for explaining the present invention and are not meant to limit the present invention.
Example (b):
in order to solve the problem of difficult healing of clinical wounds, the present example is a method for preparing leukocyte-rich platelet-rich plasma (L-PRP), wherein the content of platelets in the L-PRP prepared in the present example is about 4 times of that of whole blood, and the L-PRP is rich in leukocytes and IL-6, and experiments show that the L-PRP can activate STAT3 to promote migration of keratinocytes and accelerate re-epithelization of wounds by increasing the transcription level of IL-6, and the specific method is described below.
Referring to fig. 1, fig. 1A and 1B are schematic diagrams of the preparation process of PRP of this embodiment, and the specific preparation process is as follows:
1.1. blood collection: drawing blood from SD rat: animals are fasted, the operation area is shaved, and the operation area is observed to be free from red swelling and bleeding and feasible operation; anesthesia: 0.3mL of chloral hydrate with the concentration of 10 percent per 100g is used for intraperitoneal injection anesthesia; and (3) disinfection: after the anesthesia works, the rat is fixed in a supine position, the abdominal skin preparation part is disinfected by alcohol, the abdominal exploration is performed, the inferior vena cava is found, the scalp needle is punctured into the inferior vena cava, after the blood returns, the tail end of the scalp needle is inserted into a 10mL EDTA vacuum blood sampling purple head tube, and about 10mL blood can be collected; collecting human venous blood by using a 10mL EDTA vacuum blood collection purple head tube;
1.2. preparation of L-PRP: carrying out first centrifugation on the collected whole blood, wherein the centrifugation condition is 200g centrifugation for 10min at 4 ℃, the whole blood is clearly divided into three parts, namely a clear light yellow plasma layer, a white flocculent white membrane layer and a red blood cell layer with the maximum density from top to bottom after centrifugation, then sucking the whole blood to a position 2mm below the white membrane layer by using a 1mL sterile suction tube, moving the whole blood to a 15mL clean centrifuge tube, abandoning the rest components, wherein the part in the centrifuge tube needs to contain all upper plasma layers and all white membrane layers, then carrying out second centrifugation, the second centrifugation condition is 200g centrifugation for 10min at 4 ℃, abandoning the upper layers, leaving 1mL plasma, carefully suspending cell masses at the bottom of the centrifuge tube by using the sterile suction tube, gently blowing and beating uniformly, and obtaining 1mL light blood color L-PRP after suspension.
1.3. Preparation of P-PRP (leukocyte-deficient platelet-rich plasma): centrifuging the collected whole blood for the first time, centrifuging the whole blood for 10min at 200g and 4 ℃ according to the first centrifugation parameters, carefully sucking the whole blood to the surface of a white membrane layer by using a 1mL suction tube, transferring the whole blood to a 15mL clean centrifugal tube, and discarding the rest components, wherein the part should contain all upper plasma; centrifuging for 10min at 200g and 4 ℃ for the second time according to the centrifugation parameters, discarding the upper layer, leaving 1mL of plasma, carefully suspending cell masses at the bottom of the centrifuge tube by using a pipette, gently blowing and beating uniformly, and suspending to obtain about 1mL of faint yellow P-PRP.
Referring to FIG. 1, the content of platelets, leukocytes and IL-6 in L-PRP and P-PRP was determined in this example, and referring to FIG. 1C, the platelet content in rat whole blood was 629. + -. 170X 103Mu.l, platelet content in P-PRP 2381. + -. 141X 103Mu.l, platelet content in L-PRP 2367. + -. 918X 103Mu.l. The platelet content of the L-PRP and the P-PRP has no obvious difference, but the platelet content is obviously higher than that of the whole blood (about 4 times), and the conditions of the platelet-rich plasma are met. As shown in FIG. 1D, the white blood cell content in the rat whole blood is 5.3 + -2.2 × 103Mu L, the white blood cell content in the P-PRP is lower than the detection threshold of a complete blood cell counter, and the white blood cell content in the L-PRP is 10.6 +/-2.3 multiplied by 103Mu.l; the content of white blood cells in the L-PRP is obviously higher than that of the whole blood and the P-PRP, and the content of white blood cells in the whole blood is obviously higher than that of the P-PRP. Referring to FIG. 1E, ELISA was used to detect IL-6 content in rat L-PRP and P-PRP, IL-6 content in L-PRP was 53.95 + -16.65 pg/ml, IL-6 content in P-PRP was 21.34 + -11.69 pg/ml; the IL-6 content in L-PRP is obviously higher than that in P-PRP.
In this embodiment, after a rat creates a back wound model, the rat in this embodiment photographs 0 to 7d after surgery on the same scale daily, and the picture is imported into ImageJ to measure the wound area with the macroscopic wound edge for 3 times, and the average value is taken for statistical comparison to calculate the cumulative healing rate: the cumulative wound healing rate on Day X is (Day0 wound area-Day X wound area)/Day 0 wound area × 100%; calculating the daily healing rate: the daily healing rate of the wound on Day X is (Day (X-1) wound area-Day X100%) per Day (X-1) wound area).
Referring to FIGS. 2A-B, the changes in wound area were recorded and it was seen that the wound area decreased with time for each group, and the callus was shed generally at 5-6 days post-surgery, with the L-PRP group wound healing most rapidly (FIG. 2A). Comparing the cumulative healing rates of all groups, the cumulative healing rates of 1-7d after operation and L-PRP group are obviously higher than those of P-PRP group and NS group; there was no significant difference in cumulative healing rates between the P-PRP and NS groups. Comparing the daily healing rates of the groups, the daily healing rate of the post-operative 1d, L-PRP group was significantly higher than that of the P-PRP group and the NS group (P < 0.001), and the daily healing rate of the post-operative 3d, 5d, L-PRP group was significantly higher than that of the P-PRP group (P <0.05), but the daily healing rate was not significantly different from that of the NS group (FIG. 2B).
In this example, wound tissue was obtained 3d and 7d after molding, and h.e. staining was performed to observe and measure the periwound epithelial tongue length. Taking the wound periphery as a boundary, taking the farthest vertical distance of the epithelial ligulate process from the boundary as the migration length of the epithelial ligulate process, measuring for 3 times, and taking the average value to perform statistical comparison.
As shown in FIGS. 2C-D, obvious epithelial ligulate processes in each group at periwound were observed at 3D after surgery, wherein the epithelial ligulate processes in the L-PRP group had migrated to the surface of the new granulation tissue, while the epithelial ligulate processes in the P-PRP group and NS group only covered the surface of the contracted periwound tissue; at 7d after operation, the epithelial tongue process was significantly elongated and thickened compared to 3d after operation, with the L-PRP group having the most significant elongation, and the P-PRP and NS groups covering only a small amount of granulation tissue (fig. 2C). The length of the epithelial tongue process in the 3d, L-PRP group is obviously longer than that in the P-PRP group (P is less than 0.001) and NS group (P is less than 0.001) after operation, and the length of the epithelial tongue process in the P-PRP group is obviously longer than that in the NS group (P is less than 0.01); the length of the epithelial tongue process in the L-PRP group was significantly longer than that in the P-PRP group (P <0.05) and NS group (P <0.01) after the operation (7D), and the length of the epithelial tongue process in the P-PRP group was not significantly different from that in the NS group (FIG. 2D).
This example also measured the transcription levels of proinflammatory factors in peri-invasive tissue, as shown in FIG. 3, wherein IL-6: 8h, the L-PRP group is obviously more than the P-PRP group (P <0.01) and the NS group (P < 0.05); 24h, L-PRP was significantly more than in the remaining two groups (p < 0.05); the rest have no obvious difference.
This example next investigated a new mechanism of L-PRP for promoting wound healing, and the cell experiments were grouped: iguratmod (Idesin/Iguratimod) was used as IL-6 inhibitor, and the following groups were performed:
as shown in figure 4, IL-6RT-PCR was performed to detect IL-6 transcript levels after incubation of HaCaT cells for 8h in different media. The expression level of the L group is obviously higher than that of the Li group (P is less than 0.05), the P group (P is less than 0.001) and the C group (P is less than 0.001); the P group and the C group have no obvious difference; the Li group, although expressing significantly lower levels than the L group, also showed significantly higher levels than the C group (p < 0.001).
In the embodiment, the influence of L-PRP on the migration capacity of HaCaT cells is researched through a cell scratching experiment and a cell migration experiment (Transwell experiment), the cell scratching experiment is shown in an attached figure 5, the HaCaT cells are paved on a 24-hole plate, a vertical scratch is made in the center of the hole plate after 24h, different culture mediums are replaced, the HaCaT migration distance under different PRP effects is observed at different time points, and the migration of the HaCaT cells can be obviously promoted in the L group at each time point compared with the P group and the C group; after the IL-6 inhibitor Iguratmod with the final concentration of 30 mug/mL is added, the effect of L-PRP on promoting the migration of HaCaT cells is obviously weakened. The relative migration distance was calculated as (0h initial distance-24 h distance)/0 h initial distance × 100%. At each time point, the relative migration distance of the L group is significantly greater than that of the P group; starting from 24h, the relative migration distances of the L groups are all significantly greater than those of the C group; group P performed better than group C only at 72 h; the inhibitor group added with Iguratmo has no difference from the group C at each time point, and shows remarkable inhibition effect on the migration capacity of HaCaT cells from 24h compared with the group L.
The cell migration experiment is shown in figure 6, the same amount of different culture media are placed in a Transwell lower chamber, the same amount of single cell suspension is inoculated in the Transwell chamber, the chamber is taken out after 24 hours of incubation under the conventional condition, formaldehyde is fixed, HaCaT cells migrating under the action of different PRPs can be displayed by crystal violet staining, and the fact that the migration number of the HaCaT cells of an L group, a Li group, a P group and a C group is reduced in sequence can be obviously found. Observed under a high-power lens field (400 x), the mobility is equal to the area occupied by the migrated cells/total area x 100%, and the mobility of the L group is obviously higher than that of the Li group (P is less than 0.05), the P group (P is less than 0.001) and the C group (P is less than 0.001); the mobility of the P group is obviously higher than that of the C group (P is less than 0.01); the Li group, although having a lower mobility than the L group, is still superior to the C group (p < 0.01).
In this example, the effect of L-PRP on the activation level of STAT3 in HaCaT cells was also studied, and the activation level of STAT3 was measured by Western blot after incubation of HaCaT cells for 8h in various media, wherein the protein content is expressed as protein gray value/GAPDH gray value, and the activation ratio of STAT3 is expressed as pSTAT3/STAT 3. As shown in figure 7, the STAT3 content between the L group, the P group and the C group is not obviously different, but the STAT3 content of the Li group is obviously reduced compared with the L group (P <0.05) and the C group (P < 0.001). The contents of pSTAT3 in the group C, the group P, the group Li and the group L are increased in sequence, and the difference is obvious: the L group (P <0.01), Li group (P < 0.001), and P group (P <0.01) were all significantly higher than the C group, and P group (P < 0.001) and Li group (P <0.05) were all significantly lower than the L group. STAT3 was activated at the highest rate in the Li group, with L (P < 0.001), Li (P < 0.001), and P (P < 0.001) all significantly higher than in the C group, and L was lower than in the Li group (P < 0.001) but significantly higher than in the P group (P < 0.001).
In conclusion, the L-PRP prepared in the embodiment has the platelet content about 4 times that of whole blood, is rich in white blood cells and IL-6, and is found to accelerate wound re-epithelialization by up-regulating IL-6 transcription level and activating STAT 3. The L-PRP prepared by the embodiment and the research on the L-PRP refine the classification and application scenes of the PRP, discover a new mechanism for promoting the healing of the wound by the L-PRP, provide a new solution for clinically solving the difficult wound, are expected to be applied to the medicine for treating the difficult wound, and have important clinical practice significance.
The above is an embodiment of the present invention. The embodiments and specific parameters in the embodiments are only for the purpose of clearly illustrating the verification process of the invention and are not intended to limit the scope of the invention, which is defined by the claims, and all equivalent structural changes made by using the contents of the specification and the drawings of the present invention should be covered by the scope of the present invention.
Claims (3)
1. A preparation method of leukocyte-rich and platelet-rich plasma is characterized by comprising the following specific steps: collecting 10mL of whole blood by using a 10mL EDTA vacuum blood collection purple head tube, then placing the purple head tube filled with the whole blood at 4 ℃ for 200g for centrifugation for 10min, clearly dividing the whole blood into three parts, sequentially forming a clear light yellow plasma layer, a white flocculent white membranous layer and a red blood cell layer with the maximum density from top to bottom, sucking the three parts to a position 2mm below the white membranous layer by using a 1mL sterile suction pipe, moving the three parts to a 15mL clean centrifugal tube, discarding the rest components, leaving 1mL of plasma in the centrifugal tube, carefully suspending cell masses at the bottom of the centrifugal tube by using the sterile suction pipe, gently blowing and uniformly suspending the suspension to obtain 1mL light blood color L-PRP, wherein the part in the centrifugal tube needs to contain all upper plasma layers and all white membranous layers, and then performing secondary centrifugation, and the secondary centrifugation condition is 200g for 10min at 4 ℃.
2. An L-PRP produced by the production process according to claim 1.
3. Use of an L-PRP according to claim 2 in a medicament for the treatment of refractory wounds.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111287905.8A CN114081899A (en) | 2021-11-02 | 2021-11-02 | Preparation method of leukocyte-rich and platelet-rich plasma |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111287905.8A CN114081899A (en) | 2021-11-02 | 2021-11-02 | Preparation method of leukocyte-rich and platelet-rich plasma |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114081899A true CN114081899A (en) | 2022-02-25 |
Family
ID=80298588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111287905.8A Pending CN114081899A (en) | 2021-11-02 | 2021-11-02 | Preparation method of leukocyte-rich and platelet-rich plasma |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114081899A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106754681A (en) * | 2016-12-29 | 2017-05-31 | 李众利 | A kind of platelet rich plasma and preparation method and application |
US20180306817A1 (en) * | 2015-10-07 | 2018-10-25 | Sangui Bio Pty Ltd. | Blood Preparation and Profiling |
WO2021088777A1 (en) * | 2019-11-04 | 2021-05-14 | Bloommed Technologies Pte. Ltd. | Method for preparing monocytes derived signaling cells mixture and uses thereof |
-
2021
- 2021-11-02 CN CN202111287905.8A patent/CN114081899A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180306817A1 (en) * | 2015-10-07 | 2018-10-25 | Sangui Bio Pty Ltd. | Blood Preparation and Profiling |
CN106754681A (en) * | 2016-12-29 | 2017-05-31 | 李众利 | A kind of platelet rich plasma and preparation method and application |
WO2021088777A1 (en) * | 2019-11-04 | 2021-05-14 | Bloommed Technologies Pte. Ltd. | Method for preparing monocytes derived signaling cells mixture and uses thereof |
Non-Patent Citations (5)
Title |
---|
DE OLIVEIRA LA 等: ""Cell and platelet composition assays by flow cytometry: basis for new platelet-rich fibrin methodologies"", 《JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS》 * |
DEVEREAUX J等: ""Leucocyte-Rich Platelet-Rich Plasma Enhances Fibroblast and Extracellular Matrix Activity: Implications in Wound Healing"", 《INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES》 * |
PAVLOVIC 等: ""Platelet Rich Plasma: a short overview of certain bioactive components"", 《OPEN MEDICINE》 * |
张昭远 等: ""应用不同离心条件优化富白细胞富血小板血浆制作方案研究"", 《中国修复重建外科杂志》 * |
瞿刚波: ""富血小板血浆治疗四肢皮肤缺损的临床应用研究"", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113244272B (en) | Composition for improving premature ovarian failure and preparation method and application thereof | |
CN108653327A (en) | A kind of preparation method of secreting type rich platelet gel for chronic skin injury treatment | |
CN112587720A (en) | CGF and umbilical cord mesenchymal stem cell exosome mixture, preparation and application | |
CN114081899A (en) | Preparation method of leukocyte-rich and platelet-rich plasma | |
CN114854688B (en) | Method for improving expression level of mast cell exosomes and membrane surface Fc epsilon RI and application thereof | |
CN105112354B (en) | Retinal pigment epithelium epithelial-mesenchymal transformation model and its application | |
CN110917217A (en) | Application of muscle stem cells in preparation of anti-inflammatory drugs | |
CN114028413B (en) | Application of exogenous has-mir-200b-3p in preparation of acute and chronic wound medicines for diabetes | |
CN116004755A (en) | Method for constructing anti-redness evaluation model based on cytokine-stimulated chicken embryo angiogenesis | |
CN114836378A (en) | In-vitro culture method of autologous breast milk stem cells, injection and application of injection in skin injury repair | |
CN114712404A (en) | Use of nocardia rubra cell wall skeleton as neutrophil regulator | |
CN110680949B (en) | Preparation method and application of wound dressing based on breast milk | |
CN113652398A (en) | Method and compound for enhancing mucosa repair effect of mesenchymal stem cell exosome | |
CN110419492B (en) | Method for establishing oral mucosa fibrous animal model by adopting areca catechu extract and mechanical friction | |
CN107441481B (en) | A menstrual blood stem cell preparation for treating simple skin injury and its preparation method | |
CN109701089B (en) | Degradable tissue regeneration barrier membrane and preparation method thereof | |
CN108421034A (en) | Application of the kallikrein 7 in skin wound healing | |
CN105732836B (en) | The extraction process of grifolan and its purposes on preparing the drug for repairing gastric mucosa wound | |
CN118356498B (en) | Application of REPS2 expression inhibitor in preparation of medicine for preventing and treating brain toxic neuroinflammation caused by 1, 2-dichloroethane | |
CN109908177A (en) | A kind of preparation method of the stem cell secretion factor Essence for wound healing | |
CN115887551B (en) | Natural TARC/CCL17 and MDC/CCL22 inhibitor and preparation and application thereof | |
CN114480270A (en) | Preparation method of MSCs culture supernatant, product and application thereof | |
CN111228283A (en) | Application of ginsenoside Rg3 in preparation of medicine for treating acute respiratory inflammation | |
CN118109401B (en) | Umbilical mesenchymal stem cell exosome and preparation method and application thereof | |
CN115957185A (en) | Oral mucositis spray prepared by combining umbilical cord mesenchymal stem cell exosome and cord blood PRP |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220225 |